Our Science – Kochenderfer Website
James N. Kochenderfer, M.D.
Selected Publications |
 |
| 1)
Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN. B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma. Clin. Cancer Res. 19: 2048-60, 2013. [Journal] |
|
| 2)
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 10: 267-76, 2013. [Journal] |
|
| 3)
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119: 2709-20, 2012. [Journal] |
|
| 4)
Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. N. Engl. J. Med. 365: 1937-8; author reply 1938, 2011. [Journal] |
|
| 5)
Rosenberg SA, Kochenderfer JN. Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. Mol. Ther. 19: 1928-30, 2011. [Journal] |
|
| 6)
Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA. Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a. Hum. Gene Ther. 22: 107-15, 2011. [Journal] |
|
| 7)
Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 116: 3875-86, 2010. [Journal] |
|
| 8)
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116: 4099-102, 2010. [Journal] |
|
| 9)
Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183: 5563-74, 2009. [Journal] |
|
| 10)
Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32: 689-702, 2009. [Journal] |
|
| 11)
Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp. Biol. Med. (Maywood). 232: 1130-41, 2007. [Journal] |
|
| 12)
Kochenderfer JN, Chien CD, Simpson JL, Gress RE. Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin. Immunol. 124: 119-30, 2007. [Journal] |
|
| 13)
Kochenderfer JN, Simpson JL, Chien CD, Gress RE. Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood. 110: 450-60, 2007. [Journal] |
|
| 14)
Kochenderfer JN, Chien CD, Simpson JL, Gress RE. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses. J. Immunol. 177: 8860-73, 2006. [Journal] |
|
| 15)
Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 100: 3639-45, 2002. [Journal] |
|
| 16)
Kochenderfer JN, Molldrem JJ. Leukemia vaccines. Curr Oncol Rep. 3: 193-200, 2001. [Journal] |
|
| Click Here to View Collapsed Bibliography. |
This page was last updated on 5/6/2013.
